SI2533774T1 - Uporaba agomelatina za pripravo zdravil za zdravljenje obsesivno-kompulzivne motnje (okm) - Google Patents
Uporaba agomelatina za pripravo zdravil za zdravljenje obsesivno-kompulzivne motnje (okm) Download PDFInfo
- Publication number
- SI2533774T1 SI2533774T1 SI201131444T SI201131444T SI2533774T1 SI 2533774 T1 SI2533774 T1 SI 2533774T1 SI 201131444 T SI201131444 T SI 201131444T SI 201131444 T SI201131444 T SI 201131444T SI 2533774 T1 SI2533774 T1 SI 2533774T1
- Authority
- SI
- Slovenia
- Prior art keywords
- agomelatine
- compulsive disorder
- treatment
- okm
- obsessive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (6)
- UPORABA AGOMELATINA ZA PRIPRAVO ZDRAVIL ZA ZDRAVLJENJE OBSESIVNO-KOMPULZIVNE MOTNJE (OKM) Patentni zahtevki1. Uporaba agomelatina oziroma A/-[2-(7-metoksi-1-naftil)etil]acetamida oziroma enega izmed njegovih hidratov, kristaliničnih oblik in dodatnih soli s farmacevtsko sprejemljivo kislino ali bazo, kot edino aktivno sestavino, za pridobivanje zdravila za zdravljenje obsesivno-kompulzivne motnje (OKM).
- 2. Uporaba po zahtevku 1, označena s tem, da se agomelatin pridobi v kristalinični obliki II, kot je opisano v patentni prijavi EP1564202.
- 3. Farmacevtski sestavki, ki jih sestavlja agomelatin oziroma eden izmed njegovih hidratov, kristaliničnih oblik in dodatnih soli s farmacevtsko sprejemljivo kislino ali bazo, samostojno ali v kombinaciji z eno ali več farmacevtsko sprejemljivimi pomožnimi snovmi, za uporabo pri zdravljenju obsesivno-kompulzivne motnje (OKM).
- 4. Farmacevtski sestavek za uporabo po zahtevku 3, označen s tem, da se agomelatin pridobi v kristalinični obliki II, kot je opisano v patentni prijavi EP1564202.
- 5. Agomelatin oziroma A/-[2-(7-metoksi-1-naftil)etil]acetamid oziroma eden izmed njegovih hidratov, kristaliničnih oblik in dodatnih soli s farmacevtsko sprejemljivo kislino ali bazo za uporabo pri zdravljenju obsesivno-kompulzivne motnje (OKM).
- 6. Kristalinična oblika II agomelatina, kot je opisana v patentni prijavi EP1564202, za uporabo pri zdravljenju obsesivno-kompulzivne motnje (OKM).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1000560A FR2956031B1 (fr) | 2010-02-11 | 2010-02-11 | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble obsessionnel compulsif (toc) |
EP11708533.2A EP2533774B1 (fr) | 2010-02-11 | 2011-02-10 | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble obsessionnel compulsif (toc) |
PCT/FR2011/000080 WO2011098689A2 (fr) | 2010-02-11 | 2011-02-10 | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble obsessionnel compulsif (toc) |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2533774T1 true SI2533774T1 (sl) | 2018-05-31 |
Family
ID=42244669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201131444T SI2533774T1 (sl) | 2010-02-11 | 2011-02-10 | Uporaba agomelatina za pripravo zdravil za zdravljenje obsesivno-kompulzivne motnje (okm) |
Country Status (34)
Country | Link |
---|---|
US (1) | US20120309838A1 (sl) |
EP (1) | EP2533774B1 (sl) |
JP (1) | JP5634529B2 (sl) |
KR (1) | KR20120117936A (sl) |
CN (1) | CN102781437B (sl) |
AR (1) | AR080150A1 (sl) |
AU (1) | AU2011214190B2 (sl) |
BR (1) | BR112012020169A2 (sl) |
CA (1) | CA2789082C (sl) |
CY (1) | CY1120009T1 (sl) |
DK (1) | DK2533774T3 (sl) |
EA (1) | EA023473B1 (sl) |
ES (1) | ES2667856T3 (sl) |
FR (1) | FR2956031B1 (sl) |
GE (1) | GEP20166456B (sl) |
HK (1) | HK1177897A1 (sl) |
HR (1) | HRP20180537T1 (sl) |
HU (1) | HUE037098T2 (sl) |
LT (1) | LT2533774T (sl) |
MA (1) | MA34129B1 (sl) |
ME (1) | ME03047B (sl) |
MX (1) | MX2012009087A (sl) |
MY (1) | MY158112A (sl) |
NO (1) | NO2533774T3 (sl) |
NZ (1) | NZ601452A (sl) |
PL (1) | PL2533774T3 (sl) |
PT (1) | PT2533774T (sl) |
RS (1) | RS56932B1 (sl) |
SG (1) | SG182748A1 (sl) |
SI (1) | SI2533774T1 (sl) |
TR (1) | TR201802155T4 (sl) |
UA (1) | UA104368C2 (sl) |
WO (1) | WO2011098689A2 (sl) |
ZA (1) | ZA201205566B (sl) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2810656T3 (pl) * | 2013-06-06 | 2018-01-31 | Zentiva Ks | Preparaty agomelatyny zawierające agomelatynę w postaci kokryształów |
CN103655499B (zh) * | 2013-12-23 | 2015-07-22 | 天津泰普药品科技发展有限公司 | 一种稳定的晶x型阿戈美拉汀片剂及其制备方法 |
KR102039582B1 (ko) | 2018-12-12 | 2019-11-01 | 주식회사 라파스 | 인장 공정으로 제조하기에 적합한 마이크로니들 재료의 적합성 시험 방법 및 이를 포함하는 마이크로니들 제조 방법 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2658818B1 (fr) | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
US5618824A (en) * | 1994-03-09 | 1997-04-08 | Merrell Pharmaceuticals Inc. | Treatment of obsessive-compulsive disorders with 5-HT2 antagonists |
AR047553A1 (es) * | 2003-07-04 | 2006-01-25 | Lundbeck & Co As H | La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina |
FR2866335B1 (fr) * | 2004-02-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
JP2008531714A (ja) * | 2005-03-04 | 2008-08-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 不安障害の治療用及び/又は予防用の医薬組成物 |
FR2899472B1 (fr) * | 2006-04-07 | 2008-09-12 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee |
KR20090029200A (ko) * | 2006-05-22 | 2009-03-20 | 반다 파마슈티칼즈, 인코퍼레이티드. | 우울증 질환에 대한 치료 |
WO2008035177A2 (en) * | 2006-09-18 | 2008-03-27 | Copharm | Combination of mt1 and mt2 melatonin receptor agonists and a norepinephrine/dopamine reuptake inhibitor |
-
2010
- 2010-02-11 FR FR1000560A patent/FR2956031B1/fr not_active Expired - Fee Related
-
2011
- 2011-02-09 AR ARP110100406A patent/AR080150A1/es unknown
- 2011-02-10 ES ES11708533.2T patent/ES2667856T3/es active Active
- 2011-02-10 SI SI201131444T patent/SI2533774T1/sl unknown
- 2011-02-10 CA CA2789082A patent/CA2789082C/fr not_active Expired - Fee Related
- 2011-02-10 MY MYPI2012700497A patent/MY158112A/en unknown
- 2011-02-10 NZ NZ601452A patent/NZ601452A/en not_active IP Right Cessation
- 2011-02-10 WO PCT/FR2011/000080 patent/WO2011098689A2/fr active Application Filing
- 2011-02-10 PL PL11708533T patent/PL2533774T3/pl unknown
- 2011-02-10 EP EP11708533.2A patent/EP2533774B1/fr active Active
- 2011-02-10 CN CN201180007930.4A patent/CN102781437B/zh not_active Expired - Fee Related
- 2011-02-10 UA UAA201210538A patent/UA104368C2/ru unknown
- 2011-02-10 HU HUE11708533A patent/HUE037098T2/hu unknown
- 2011-02-10 US US13/578,383 patent/US20120309838A1/en not_active Abandoned
- 2011-02-10 JP JP2012552440A patent/JP5634529B2/ja not_active Expired - Fee Related
- 2011-02-10 MA MA35133A patent/MA34129B1/fr unknown
- 2011-02-10 KR KR1020127023793A patent/KR20120117936A/ko not_active Application Discontinuation
- 2011-02-10 BR BR112012020169-7A patent/BR112012020169A2/pt not_active IP Right Cessation
- 2011-02-10 EA EA201201123A patent/EA023473B1/ru not_active IP Right Cessation
- 2011-02-10 ME MEP-2018-36A patent/ME03047B/me unknown
- 2011-02-10 TR TR2018/02155T patent/TR201802155T4/tr unknown
- 2011-02-10 NO NO11708533A patent/NO2533774T3/no unknown
- 2011-02-10 MX MX2012009087A patent/MX2012009087A/es not_active Application Discontinuation
- 2011-02-10 RS RS20180216A patent/RS56932B1/sr unknown
- 2011-02-10 GE GEAP201112854A patent/GEP20166456B/en unknown
- 2011-02-10 SG SG2012055505A patent/SG182748A1/en unknown
- 2011-02-10 AU AU2011214190A patent/AU2011214190B2/en not_active Ceased
- 2011-02-10 DK DK11708533.2T patent/DK2533774T3/en active
- 2011-02-10 PT PT117085332T patent/PT2533774T/pt unknown
- 2011-02-10 LT LTEP11708533.2T patent/LT2533774T/lt unknown
-
2012
- 2012-07-24 ZA ZA2012/05566A patent/ZA201205566B/en unknown
-
2013
- 2013-05-13 HK HK13105666.7A patent/HK1177897A1/xx not_active IP Right Cessation
-
2018
- 2018-02-05 CY CY20181100139T patent/CY1120009T1/el unknown
- 2018-04-03 HR HRP20180537TT patent/HRP20180537T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017027798A2 (pt) | compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
BR112018002304A8 (pt) | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
HRP20151443T1 (hr) | Terapijsko sredstvo protiv stenoze kralježniäśnog kanala | |
HRP20100577T1 (hr) | Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti | |
BR112013008834A2 (pt) | produtos mastigáveis macios não à base de amido | |
JP2011518119A5 (sl) | ||
BR112014006763A2 (pt) | n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1 | |
BR112012028451A2 (pt) | composição tópica de iodopovidona | |
BR112013017750A2 (pt) | nanocápsulas com envoltório polimérico | |
BRPI1007092A2 (pt) | "derivados de hidroxamato, uso dos derivados de hidroxamato, composições farmacêuticas, método para prevenção ou tratamento de doença e método de produção de derivados de hidroxamato" | |
EA201691490A1 (ru) | Фармацевтическая композиция, содержащая бринзоламид | |
JP2018521007A5 (sl) | ||
EA201301266A1 (ru) | Фармацевтическая композиция, содержащая налбуфина гидрохлорид, ее применение для лечения болевого синдрома средней и высокой интенсивности и способ получения фармацевтической композиции | |
AR090874A1 (es) | Formulacion | |
SI2533774T1 (sl) | Uporaba agomelatina za pripravo zdravil za zdravljenje obsesivno-kompulzivne motnje (okm) | |
NI201900063A (es) | Amidas aromáticas de ácido carboxílico | |
BR112012022074A2 (pt) | composição compreendendo como ingredientes ativos l-carnitina em combinação com hidroxiquinurenina-o-beta-dl-glicosídeo, para a prevenção e/ou tratamento de patologias dos olhos devido à radiação ultravioleta | |
CO6280474A2 (es) | Composicion farmaceutica para el tratamiento de la eyaculacion precoz | |
BRPI1016064A2 (pt) | "formulação com compartimentos múltiplos, processo para a preparação da mesma, agentes de transporte ou de vetorização, e de liberação intracelular de agentes terapêuticos, utilização de uma formulação, e composição farmacêutica" | |
BR112012030485A2 (pt) | composição para prevenção ou tratamento de osteoporose e processo de fabricação para a mesma | |
BR112012020377A8 (pt) | utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial | |
BR112014029838A2 (pt) | formas no estado sólido de n-((s)-2,3-di-hidróxi-propil)-3-(2-flúor-4-iodo-fenilamino)- isonicotinamida | |
BR112012021445B8 (pt) | formulação farmacêutica ou neutracêutica, e uso de um agente promotor de biodisponibilidade | |
UY31059A1 (es) | Formulaciones de aminoacido n-halogenado | |
MX2013005482A (es) | Composicion farmaceutica que contiene sales de citrato y bicarbonato, y su uso para el tratamiento de la cistinuria. |